Age-neutral guidelines for the primary prevention of cardiovascular disease

Research output: Contribution to journalComment/debate

4 Citations (Scopus)

Abstract

Use of common guidelines for primary prevention of cardiovascular events based on 10-year risk results in undertreatment of younger individuals, especially women, since age and sex are major determinants of global risk. Women in their late 40s have a 10-year risk lower than the 10% threshold used for cholesterol-lowering treatment even in the presence of marked elevations of blood pressure or cholesterol. Removal of age from risk algorithms and use of lifetime global risk to treat individuals according to the degree of their modifiable risk factors rather than demographics has been proposed. Initiation of therapy at younger ages, aiming at " primordial" prevention of atherosclerotic disease rather than focusing on cardiovascular events, will result in saving more quality-adjusted life-years. Generic medications can be obtained at an affordable cost, and concerns about long-term safety and efficacy can be tested in a clinical trial of younger individuals at low 10-year risk but high lifetime risk. J Clin Hypertens (Greenwich). 2009;11:644-645.

Original languageEnglish (US)
Pages (from-to)644-645
Number of pages2
JournalJournal of Clinical Hypertension
Volume11
Issue number11
DOIs
StatePublished - Nov 1 2009

Fingerprint

Primary Prevention
Cardiovascular Diseases
Guidelines
Cholesterol
Quality-Adjusted Life Years
Demography
Clinical Trials
Blood Pressure
Safety
Costs and Cost Analysis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

@article{a30bb46351154672b888056f6fa6d9bd,
title = "Age-neutral guidelines for the primary prevention of cardiovascular disease",
abstract = "Use of common guidelines for primary prevention of cardiovascular events based on 10-year risk results in undertreatment of younger individuals, especially women, since age and sex are major determinants of global risk. Women in their late 40s have a 10-year risk lower than the 10{\%} threshold used for cholesterol-lowering treatment even in the presence of marked elevations of blood pressure or cholesterol. Removal of age from risk algorithms and use of lifetime global risk to treat individuals according to the degree of their modifiable risk factors rather than demographics has been proposed. Initiation of therapy at younger ages, aiming at {"} primordial{"} prevention of atherosclerotic disease rather than focusing on cardiovascular events, will result in saving more quality-adjusted life-years. Generic medications can be obtained at an affordable cost, and concerns about long-term safety and efficacy can be tested in a clinical trial of younger individuals at low 10-year risk but high lifetime risk. J Clin Hypertens (Greenwich). 2009;11:644-645.",
author = "William Kostis and John Kostis",
year = "2009",
month = "11",
day = "1",
doi = "10.1111/j.1751-7176.2009.00162.x",
language = "English (US)",
volume = "11",
pages = "644--645",
journal = "Journal of Clinical Hypertension",
issn = "1524-6175",
publisher = "Wiley-Blackwell",
number = "11",

}

Age-neutral guidelines for the primary prevention of cardiovascular disease. / Kostis, William; Kostis, John.

In: Journal of Clinical Hypertension, Vol. 11, No. 11, 01.11.2009, p. 644-645.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - Age-neutral guidelines for the primary prevention of cardiovascular disease

AU - Kostis, William

AU - Kostis, John

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Use of common guidelines for primary prevention of cardiovascular events based on 10-year risk results in undertreatment of younger individuals, especially women, since age and sex are major determinants of global risk. Women in their late 40s have a 10-year risk lower than the 10% threshold used for cholesterol-lowering treatment even in the presence of marked elevations of blood pressure or cholesterol. Removal of age from risk algorithms and use of lifetime global risk to treat individuals according to the degree of their modifiable risk factors rather than demographics has been proposed. Initiation of therapy at younger ages, aiming at " primordial" prevention of atherosclerotic disease rather than focusing on cardiovascular events, will result in saving more quality-adjusted life-years. Generic medications can be obtained at an affordable cost, and concerns about long-term safety and efficacy can be tested in a clinical trial of younger individuals at low 10-year risk but high lifetime risk. J Clin Hypertens (Greenwich). 2009;11:644-645.

AB - Use of common guidelines for primary prevention of cardiovascular events based on 10-year risk results in undertreatment of younger individuals, especially women, since age and sex are major determinants of global risk. Women in their late 40s have a 10-year risk lower than the 10% threshold used for cholesterol-lowering treatment even in the presence of marked elevations of blood pressure or cholesterol. Removal of age from risk algorithms and use of lifetime global risk to treat individuals according to the degree of their modifiable risk factors rather than demographics has been proposed. Initiation of therapy at younger ages, aiming at " primordial" prevention of atherosclerotic disease rather than focusing on cardiovascular events, will result in saving more quality-adjusted life-years. Generic medications can be obtained at an affordable cost, and concerns about long-term safety and efficacy can be tested in a clinical trial of younger individuals at low 10-year risk but high lifetime risk. J Clin Hypertens (Greenwich). 2009;11:644-645.

UR - http://www.scopus.com/inward/record.url?scp=70449377075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449377075&partnerID=8YFLogxK

U2 - 10.1111/j.1751-7176.2009.00162.x

DO - 10.1111/j.1751-7176.2009.00162.x

M3 - Comment/debate

C2 - 19878373

AN - SCOPUS:70449377075

VL - 11

SP - 644

EP - 645

JO - Journal of Clinical Hypertension

JF - Journal of Clinical Hypertension

SN - 1524-6175

IS - 11

ER -